Genoscience is a biopharmaceutical company, focused on the development of new drugs for the treatment of viral diseases such HCV infection. Genoscience concept is based on a technology platform including a high expertise in viral resistance. Our innovative technology platform, which combines internal expertise in resistance with unique molecular modeling through our proprietary software (GenMolTM), allows us to develop highly targeted molecules taking into account the phenomenon of resistance.
Our current focus is to develop new antiviral compounds for the treatment of hepatitis C infections (HCV). We have discovered two new families of compounds targeted at the HCV protease (HCV protease inhibitors). In addition, through our dedicated software (PredictSearch®) and proprietary (GenMol®) access to extensive clinical databases, we provide other pharmaceutical companies with new intelligent tools for monitoring antiviral therapies and identifying biomarkers for prognosis.